When will Stiripentol be officially launched in China?

Stiripentol (Stiripentol) has not yet been officially launched in China and has not been included in medical insurance. This means that to obtain stiripentol, patients still need to rely on imported channels or purchase foreign versions of the drug. Stipentol has been approved in many countries around the world for the treatment of epileptic seizures associated with Dravet syndrome, especially in patients who are ineffective with conventional anti-epileptic drugs. Stipentol has shown significant efficacy.

In China, the clinical use of stiripentol has not yet received sufficient regulatory approval. Although the drug has been approved in countries such as Europe and the United States and is widely used in clinical treatments, the official launch time in China is still uncertain. The specific time to market will be affected by the approval process of the China National Medical Products Administration (NMPA) and the review speed of drug registration applications.

For patients withDravet syndrome, the use of stiripentol has become one of the important treatment options. Dravet syndrome is a severe hereditary epilepsy syndrome that usually occurs in infancy and is accompanied by refractory seizures. Stipentol's unique mechanism of action makes it an effective drug in the treatment of this disease, especially when combined with other anti-epileptic drugs, which can significantly improve patients' seizure control.

Although stiripentol is not marketed in China, the potential market for this drug is still very large, especially in the treatment of Dravet syndromeDravet syndrome. As China's focus on the treatment of rare and difficult-to-treat diseases continues to deepen, stiripentol is expected to enter the Chinese market in the next few years.

Currently, stiripentol is still not covered by China’s medical insurance, so patients need to purchase it themselves. Based on the current prices of imported drugs, the cost of stiripentol is relatively high, which may impose a financial burden on the treatment of some patients. However, with the gradual development of the market and the adjustment of drug policies, stiripentol may enter the scope of medical insurance reimbursement in the future, reducing the financial pressure on patients.

Reference materials:https://www.diacomit.com/